Status:
UNKNOWN
Exercise for Patients With Renal Cell Cancer Receiving Sunitinib
Lead Sponsor:
Charite University, Berlin, Germany
Collaborating Sponsors:
Pfizer
Conditions:
Renal Cell Carcinoma
Eligibility:
All Genders
18-75 years
Phase:
PHASE3
Brief Summary
In this randomized, controlled trial the investigators evaluate the effects of an exercise program lasting for 12 weeks on the physical performance, the cardiovascular function (24h blood pressure, re...
Eligibility Criteria
Inclusion
- 18 to 75 years
- Understanding of written German
- Treatment with Sunitinib
- Ability to walk
Exclusion
- Cardiovascular, pulmonary or osteoarticular disease which can be aggravated by exercise
- BMI \< 18 or \> 30
Key Trial Info
Start Date :
December 1 2009
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
Estimated Enrollment :
70 Patients enrolled
Trial Details
Trial ID
NCT00869011
Start Date
December 1 2009
Last Update
December 23 2009
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Section Sports Medicine, Charité Universitätsmedizin Berlin, Hindenburgdamm 30
Berlin, State of Berlin, Germany, 12200